Core Laboratories (CLB) EBITDA (2022 - 2026)

Core Laboratories has reported EBITDA for 5 years, with the latest figure at $5.4 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA fell 32.05% year-over-year to $5.4 million; the trailing twelve-month figure through Mar 2026 stood at $21.4 million (down 68.92% YoY), and the FY2025 full-year result was $23.9 million, down 67.22% from the prior year.
• EBITDA for Q1 2026 stood at $5.4 million, up from -$27.4 million in the prior quarter.
• The five-year high for EBITDA was $24.5 million in Q3 2025, with the low at -$28.2 million in Q4 2023.
• Historically, EBITDA has averaged $11.2 million across 5 years, with a median of $18.1 million in 2023.
• Annual changes were most pronounced in 2024 — EBITDA jumped 162.87% — and 2025, when it plunged 254.63%.
• Core Laboratories' EBITDA stood at $19.5 million in 2022, then plunged by 244.32% to -$28.2 million in 2023, then soared by 162.87% to $17.7 million in 2024, then sank by 254.63% to -$27.4 million in 2025, then soared by 119.87% to $5.4 million in 2026.
• The last three EBITDA figures came in at $5.4 million (Q1 2026), -$27.4 million (Q4 2025), and $24.5 million (Q3 2025), per Business Quant data.